The Effects of Diosgenin on Hypolipidemia and Its Underlying Mechanism: A Review

Fengcui Sun1
Xiafen Yang1
Chaoqun Ma1
Shizhao Zhang1
Lu Yu2
Haifei Lu3
Guoliang Yin1
Pengpeng Liang1
Yanan Feng1
Fengxia Zhang1

1Shandong University of Traditional Chinese Medicine, Jinan, 250000, People's Republic of China; 2Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, People's Republic of China; 3Hubei University of Traditional Chinese Medicine, Wuhan, 430065, People's Republic of China; 4Department of Neurology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250011, People's Republic of China.

Abstract: Hyperlipidemia is a disorder of lipid metabolism, which is a major cause of coronary heart disease. Although there has been considerable progress in hyperlipidemia treatment, morbidity and risk associated with the condition continue to rise. The first-line treatment for hyperlipidemia, statins, has multiple side effects; therefore, development of safe and effective drugs from natural products to prevent and treat hyperlipidemia is necessary. Diosgenin is primarily derived from fenugreek (Trigonella foenum graecum) seeds, and is also abundant in medicinal herbs such as Dioscorea rhizome, Dioscorea septemloba, and Rhizoma polygonati, is a well-known steroidal sapogenin and the active ingredient in many drugs to treat cardiovascular conditions. There is abundant evidence that diosgenin has potential for application in correcting lipid metabolism disorders. In this review, we evaluated the latest evidence related to diosgenin and hyperlipidemia from clinical and animal studies. Additionally, we elaborate the pharmacological mechanism underlying the activity of diosgenin in treating hyperlipidemia in detail, including its role in inhibition of intestinal absorption of lipids, regulation of cholesterol transport, promotion of cholesterol conversion into bile acid and its excretion, inhibition of endogenous lipid biosynthesis, antioxidation and lipoprotein lipase activity, and regulation of transcription factors related to lipid metabolism. This review provides a deep exploration of the pharmacological mechanisms involved in diosgenin-hyperlipidemia interactions and suggests potential routes for the development of novel drug therapies for hyperlipidemia.

Keywords: diosgenin, hyperlipidemia, serum cholesterol, lipoprotein cholesterol, mechanism

Introduction

Hyperlipidemia is a pathological disorder of lipid metabolism that has various causes. The clinical manifestations of hyperlipidemia include increased serum cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C), and decreased serum high-density lipoprotein cholesterol (HDL-C). Imbalance of LDL-C and HDL-C can increase the risk of cardiovascular (CV) events, including myocardial infarction and stroke.1 Data released by the American Heart Association in 2018 showed that CV disease (CVD) is the most lethal disease worldwide.2 According to the 2010 global burden of disease study, 15.6 million people died of CVD, accounting for 29.6% of all deaths.3 Hyperlipidemia has a long disease course, and many underlying causes, reflecting its complex etiology.4 Dyslipidemia is a significant risk factor for coronary artery disease and stroke; hence, prevention and appropriate management of dyslipidemia can markedly lower the related morbidity and mortality.5 Holven et al described the importance of early...
identification and treatment of patients with familial hypercholesterolemia for reducing cholesterol burden and risk of CHD. Lipid-lowering therapy is a cornerstone of CV risk modification strategies, which can reduce LDL-C by 30–50% and proportionally reduce CV events. Although statins are generally well tolerated, they are not always sufficient to achieve LDL-C goals for many patients, and cause numerous specific negative effects on muscle, liver, and kidney, as well as increasing the risk of new-onset diabetes mellitus and hemorrhagic stroke. Therefore, there is an urgent need to develop new powerful drugs to treat hyperlipidemia and reduce the harms to human health and longevity worldwide associated with CV events.

Natural products can facilitate a multi-component, multi-target, multi-channel, and multi-dimensional overall treatment networks. Thus, natural products represent alternative resources for developing new drugs, with higher efficiency, better safety, and fewer side effects. Moreover, natural products can play essential roles in preventing and treating many human diseases, including CVDs, metabolic syndromes, cancer, diabetes, obesity, and neurological disorders.

Diosgenin, a well-known steroid sapogenin, occurs widely in various medical plants and is mainly isolated from Dioscoreaeae, Agavaceae, Amaryllidaceae, Liliaceae, Solanaceae, Scrophulariaceae, Amaryllidaceae, Leguminosae, and Rhamnaceae. The best-known source of various steroidal saponins, including spirostane and furostane types, is fenugreek (Trigonella foenum graecum) seeds. In recent years, diosgenin has attracted increasing attention due to its efficacy in treating various metabolic diseases, including diabetes, CVDs, neurological disease, osteoporosis, and hyperlipidemia, in addition to anti-cancer effects, which are mediated via multiple targets and regulate various signals. Numerous animal experiments and clinical trials have shown that diosgenin can reduce blood lipids by lowering plasma low-density lipoprotein (LDL) and increasing high-density lipoprotein (HDL). Cholesterol lowering drug cholestyramine can combine with bile acid (BA) to form insoluble complex and prevent its reabsorption. Compared with the impact of cholestyramine, diosgenin can interfere with the absorption of exogenous and endogenous cholesterol, promote the secretion of cholesterol into bile, and increase the excretion of neutral sterols without affecting the bile and fecal excretion of bile acid. The effect of diosgenin combined with clofibrate in reducing plasma LDL is more robust than that of a single drug; hence, diosgenin can be combined with other lipid-lowering medications to enhance their effects. Further, diosgenin has demonstrated outstanding potential for lowering lipids in clinical trials and animal experiments and represents a new avenue of exploration for achieving lipid reduction.

In this paper, we elaborate the detailed mechanism underlying lipid metabolism regulation by diosgenin. As shown in Figure 1, this includes the effects of diosgenin in inhibiting intestinal lipid absorption, regulating cholesterol transport, promoting cholesterol conversion into bile acid and its excretion, inhibiting endogenous lipid biosynthesis, antioxidation effects, regulating lipoprotein lipase activity, and regulating transcription factors related to lipid metabolism.

**Physicochemical Properties of Diosgenin**

Diosgenin (3β-Hydroxy-5-spirostene) (Figure 2) is a C27 spironosteroidal saponin of the spirosterol steroid family that participates in various physiological and biochemical activities. Diosgenin is structurally similar to cholesterol and other steroids, with molecular formula C27H42O3, density 1.1 ± 0.1g/cm3, and relative molecular mass 414.63. Diosgenin is the primary precursor of various pharmacologically active steroids, including corticosteroids and oral contraceptives and takes the form of a white acicular crystal or light amorphous powder, which is thermally and chemically stable under various physical conditions. The melting point of diosgenin is above 200°C and the compound is relatively stable under light, but unstable under hydrochloric acid, which causes its rapid decomposition. Diosgenin has low solubility, due to its strong hydrophobicity; its solubility in water is approximately 0.7 ng/mL. Nevertheless, it is highly soluble in most nonpolar organic solvents (such as chloroform, dichloroethane, propanol, ethyl acetate, and propyl acetate) and some polar solvents (including acetone, methanol, and anhydrous ethanol).

**Sources of Diosgenin**

Diosgenin is a natural steroidal saponin, which is derived from the hydrolysis of dioscin. Diosgenin can be commercially extracted from several plants, including *Trigonella*, *Costus*, *Aletris*, *Smilax*, and many species of *Dioscorea*. The primary source of diosgenin is fenugreek seeds. The content of saponins in fenugreek seeds is 169 g/kg. After hydrolysis for 1 h, the saponins are completely removed and sapogenin release is maximal.
Extracts of hydrolyzed fenugreek and quinoa contain the highest fraction of sapogenin and minor fractions of phytoestrol and tocopherol.\textsuperscript{33} Diosgenin is an important material for the synthesis of steroid hormone medicines. For example, dehydroepiandrosterone can be produced semi-synthetically from natural precursors, primarily diosgenin.\textsuperscript{34} Traditionally, diosgenin has been extracted from the rhizome of \textit{Dioscorea zingiberensis} C. H. Wright by acid hydrolysis. More recently, a new method of direct penicillin biotransformation, that is environmental-friendly, simple, and energy-saving, has been developed and is considered a potential substitute for acid hydrolysis in the diosgenin extraction industry.\textsuperscript{35}

The Pharmacological Mechanism Underlying the Use of Diosgenin for Treatment of Hyperlipidemia

Diosgenin has numerous pharmacological effects, including anti-tumor activity, improving CV function, regulating immunity, causing anti-platelet aggregation, and lowering blood lipids.\textsuperscript{22} In recent years, the lipid-regulating function of diosgenin has attracted increasing attention among researchers. In humans, lipid homeostasis is regulated by homeostatic intestinal absorption mechanisms, endogenous lipid biosynthesis and metabolism, cholesterol transport, cholesterol conversion to bile acid, and biliary excretion. The metabolic enzymes and receptors involved in lipid metabolism are regulated by various transcription factors. The function of diosgenin in treating hypolipidemia through regulating the dynamics of different parts of the metabolic cycle is illustrated in Figure 3. The experimental design, pharmaco-logical evidence, and potential mechanism of diosgenin against hyperlipidemia are summarized in Table 1.
Inhibition of Intestinal Lipid Absorption

Intestinal absorption from the diet is an important source of serum lipids. Cholesterol absorption is a key regulation target of lipid metabolism in humans, because it determines the amount of endogenous bile and cholesterol retained in the diet, thus affecting cholesterol homeostasis. Fenugreek seeds containing diosgenin induced a significant reduction of plasma cholesterol in diabetic dogs, associated with interference in cholesterol absorption. Further, an in vivo experiment showed that intraperitoneal injection of 0.5 mg/kg protodioscin, a steroidal saponin similar to diosgenin from Dioscorea nipponica rhizomes, could significantly reduce blood cholesterol by 40% in male Sprague–Dawley (SD) rats fed a high-fat diet (HFD). Researchers also investigated the inhibitory effect of diosgenin on lipid absorption using experiments on cynomolgus macaques. The macaques were fed a semi-purified diet containing 0.1% cholesterol or a similar diet containing 1% diosgenin during two 3-week periods, and received a standard chow diet for 5 weeks between the two experimental periods. The results showed that diosgenin reduced cholesterol from 292 to 172mg/dl and intestinal absorption of exogenous cholesterol from 62.4% to 26.0%, as well as increasing net endogenous cholesterol secretion from ~0.8 to 93.5 mg/day. Niemann-Pick C1-Like 1 (NPC1L1) is a polytopic transmembrane protein with a critical role in cholesterol absorption. Blocking NPC1L1 endocytosis significantly reduces cholesterol endocytosis and hepatic NPC1L1 has a direct role in regulating bile cholesterol excretion and hepatic/blood cholesterol levels. Expression of NPC1L1 in the 0.15 or 0.3 g/kg diosgenin group showed a dose-dependent decrease compared with the HFD group, demonstrating that diosgenin could reduce intestinal absorption by inhibiting NPC1L1. Both diosgenin and total saponins of yellow yam can significantly reduce blood cholesterol content, where the absolute dose of diosgenin comprises only half of the total saponins in yellow yam. The anti-hypercholesterolemia effect of diosgenin was superior to that of total saponins from yellow yam, likely because the polarity and spatial structure of diosgenin are very similar to those of cholesterol, suggesting that diosgenin can likely be dispersed into metacolloids via bile acid activity, and then absorbed directly by
Table 1 The Effect of Diosgenin on Markers Relevant to Lipid Metabolism

<table>
<thead>
<tr>
<th>Model</th>
<th>Diosgenin Dose</th>
<th>Duration</th>
<th>Effects on the Plasma Lipid Profile and Transcription Factors</th>
<th>Pharmacological Effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>HFD(^A) Male SD(^B) rats</td>
<td>Protodioscin (0.5 mg/kg/d; intraperitoneal injection)</td>
<td>15–28 days</td>
<td>TC↓, LDL↓, HDL↑, HDL/LDL↑</td>
<td>Inhibited HMG-CoA reductase on endoplasmic reticulum</td>
<td>[37]</td>
</tr>
<tr>
<td>HFD SPF(^C) Male SD rats</td>
<td>0.15, 0.3 g/kg/d; intragastrically</td>
<td>4 or 8 weeks</td>
<td>FTC↓, TTC↓, TC↓, TG↓, LDL-C↓, NPC1L1↓, ABCG5↑, ABCG8↑, LXR-α↓</td>
<td>Ameliorated hepatic steatosis and decreased the villi height and tunica mucosa thickness; Reduced cholesterol absorption; Increased cholesterol excretion</td>
<td>[21]</td>
</tr>
<tr>
<td>HCD(^D) Male Wistar rats</td>
<td>0.5g/100g orally</td>
<td>4 weeks</td>
<td>TC↓, TG↓, HDL-C↑, LDL-C↓</td>
<td>Reduced Cholesterol absorption in the intestine and/ or increased Cholesterol excretion from the liver; Increased bile acid and Cholesterol excretions</td>
<td>[44]</td>
</tr>
<tr>
<td>STZ(^E) Male Wistar rats</td>
<td>40 mg/kg b.w. orally</td>
<td>45 days</td>
<td>TC↓, TG↓, Phospholipids↓, FFA↓, HMGCoA↓</td>
<td>Decreased cholesterol synthesis</td>
<td>[52]</td>
</tr>
<tr>
<td>HFD+ STZ Male SD rats</td>
<td>40, 80 mg/kg b.w. orally</td>
<td>14 days</td>
<td>TC↓, TG↓, SOD↑, GPX↑, GSH↑, TBARS↓, PPARγ↑, PPARα↑</td>
<td>Promoted pre-adipocytes differentiation; Antioxidation regulating oxidative stress</td>
<td>[68]</td>
</tr>
<tr>
<td>HFD Male SD rats</td>
<td>22.1, 44.2, 88.4 mg/kg/d orally</td>
<td>6 weeks</td>
<td>TC↓, TG↓, LDL-C↓, GSH-Px↑, NOS↑, MDA↓, SOD↑, LPL↑, HL↑</td>
<td>Antioxidation and modulating oxidative stress; Attenuated H2O2-induced cytotoxicity and increased the cell viability; Accelerated lipids metabolism; Decreased cholesterol absorption and increased biliary cholesterol secretion;</td>
<td>[74]</td>
</tr>
<tr>
<td>HFD Male C57 mice</td>
<td>In drinking water; 5 mg/L every 2 days</td>
<td>4 weeks</td>
<td>PPARγ↓, PPARγ2↓, Mest↓, MCP-1↓, IL-6↓, ROS↓</td>
<td>Ameliorated metabolic dysfunction; Inhibited adipocyte differentiation</td>
<td>[97]</td>
</tr>
<tr>
<td>Gestational diabetes-induced C57BL/KsJ(^{+/+}) (wild type, homozygous) and C57BL/KsJ(^{db/db}) (heterozygous) mice</td>
<td>Protocol 1: 10, 20 mg/kg b.w; Protocol 2: 20mg/kg intragastric tube</td>
<td>4 weeks</td>
<td>TBARS↓, SOD↑, CAT↑, GSH↑, TC↓, TG↓, LDL↓, SREBP-1↓, FAS↓, SCD-1↓, ACC↓</td>
<td>Antioxidation and regulation of oxidative stress; Inhibited the mRNA induction of lipogenic genes</td>
<td>[86]</td>
</tr>
<tr>
<td>HCD Male SD rats</td>
<td>0.1%, 0.5% diet orally</td>
<td>6 weeks</td>
<td>ALT↑, AST↑, TC↓, HDL-C↑, HDL/TC↑, GSH-Px↑, SOD↑, TBARS↑</td>
<td>Liver protective effect; Antioxidation and regulation of oxidative stress; protection against lymphocyte DNA damage in both unstressed and stressed cells; Inhibited pancreatic lipase activity</td>
<td>[71]</td>
</tr>
</tbody>
</table>

(Continued)
Table 1 (Continued).

<table>
<thead>
<tr>
<th>Model</th>
<th>Diosgenin Dose</th>
<th>Duration</th>
<th>Effects on the Plasma Lipid Profile and Transcription Factors</th>
<th>Pharmacological Effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>HFD Male KK-Ay/Ta Jcl mice (obese diabetic model)</td>
<td>0.5%, 2.0% fenugreek orally</td>
<td>4 weeks</td>
<td>TG↓, SREBP-1↑, FAS↓, SCD-1↓, ACC↓, LXR↓</td>
<td>Inhibited the mRNA induction of lipogenic genes; Inhibited hepatic steatosis</td>
<td>[53]</td>
</tr>
<tr>
<td>HFD KK-Ay/Ta Jcl mice (obese diabetic model)</td>
<td>0.5%, 2% fenugreek orally</td>
<td>4 weeks</td>
<td>aP2↑, LPL↑, Glut4↑, PPARγ↑↑, MCP-1↑↑, TNF-α↑, adiponectin↑</td>
<td>Enhanced insulin sensitivity; Promoted adipocyte differentiation and inhibited obesity-related inflammation</td>
<td>[72]</td>
</tr>
<tr>
<td>HCD Male New Zealand White rabbits</td>
<td>50 g/kg 50 mesh-size, 50 g/kg nanoscale Dioscorea pseudojaponica orally</td>
<td>8 weeks</td>
<td>TC↓, TG↓, AMPK↑↑, ACC↑↑</td>
<td>Prevented lipid accumulation within liver tissue; Accelerated lipid catabolism</td>
<td>[54]</td>
</tr>
<tr>
<td>Semipurified-diet + 0.1% cholesterol female cynomolgus macaques</td>
<td>1% die orally</td>
<td>3 weeks</td>
<td>TC↓, TG↓</td>
<td>Increased cholesterol excretion</td>
<td>[38]</td>
</tr>
<tr>
<td>Male apoE KO mice</td>
<td>1% (w/w) orally</td>
<td>8 weeks</td>
<td>TC↑, FC↑, CE↑, ABCA1↑↑, miR-19b↓</td>
<td>Enhanced macrophage cholesterol efflux; Inhibited macrophage cholesterol accumulation; accelerated RCT and improves plasma lipid profile; Inhibited aortic lipid deposition and atherogenesis</td>
<td>[63]</td>
</tr>
<tr>
<td>HFD Male SD rats</td>
<td>0.5%, 1% (w/w) orally</td>
<td>16 weeks</td>
<td>HDL↑↑, LDL↓, TG↓, ALT↓, pAMPK↑↑, pACC↑↑, AMPK↑↑, ACC↑↑, SREBP1-c↓↓, LXRe↓</td>
<td>Increased AMPK and ACC phosphorylation; accelerated lipid catabolism</td>
<td>[91]</td>
</tr>
<tr>
<td>45% kcal-fat content male Wistar rats</td>
<td>20, 40, 80 mg/kg for mice and 15, 30, 60 mg/kg for rats orally</td>
<td>8 weeks</td>
<td>AST↑↑, ALT↑↑, TG↑↑, TC↑↑, FFA↑↑, SREBP-1c↑↑, CPT↑↑, FAS↑↑, SOD↑↑, MDA↑↑, GSH↑↑, SIRT1↑↑</td>
<td>Improved hepatic lipid metabolism; decreased triacylglycerol accumulation</td>
<td>[87]</td>
</tr>
<tr>
<td>HepG2 cells; THP-1 monocytic cells</td>
<td>Protodioscin, pseudoprotodioscin, methylprotodioscin (5μm, 10μm, 25μm)</td>
<td>24h; 48h</td>
<td>ABCA1↑↑, SREBP-1↑↑, SREBP-2↑↑, LXRα↑↑, PCSK9↑↑, FAS↑↑, ACC↑↑, LDLR↑↑</td>
<td>Inhibited cholesterol triglycerides synthesis; accelerated RCT and improved plasma lipid profile;</td>
<td>[64]</td>
</tr>
<tr>
<td>Human THP-1 monocytic cells; HepG2 cells</td>
<td>Methyl protodioscin (100μm)</td>
<td>24h</td>
<td>SREBP1c↑↑, SREBP2↑↑, miR-33a/b↑↑, ABCA1↑↑, HMGCR↑↑, FAS↑↑, ACC↑↑, LXRα↑↑</td>
<td>Inhibited cholesterol triglycerides synthesis</td>
<td>[45]</td>
</tr>
<tr>
<td>C57BL/6 male mice; Wistar male rats</td>
<td>Acute experiment: 28, 56, 84 mg/kg/d; chronic test: 20, 40, 60mg/kg/d; intragastrically</td>
<td>2 weeks; chronic test: 12 weeks</td>
<td>AST↑↑, ALT↑↑, TG↑↑, TC↑↑, SOD↑↑, MDA↑↑, GSH↑↑, GSH-Px↑↑, GSR↑↑, TNF-α↑↑, IL-6↑↑, p38↑↑, pERK↑↑, pJNK↑↑, CYP2E1↑↑, PPARα↑↑, CPT↑↑, MCAD↑↑</td>
<td>Reduced the oxidative stress, Inflammatory cytokine production, apoptosis and liver steatosis</td>
<td>[70]</td>
</tr>
</tbody>
</table>

(Continued)
the intestine. When diosgenin and cholesterol are both present, diosgenin competes for bile acid binding to inhibit cholesterol absorption. Overall, these results indicate that diosgenin can inhibit lipid absorption by downregulating NPC1L1 expression and competing with cholesterol for bile acids in the intestinal tract.

Regulation of Cholesterol Transport

In addition to blood cholesterol and triglycerides, lipoproteins, such as HDL and LDL, also have important roles in lipid metabolism, as they function to transport lipids and cholesterol that are generally insoluble in blood. Kuang et al applied diosgenin to the lipogenic normal human liver (L02) cell model, and the results showed that diosgenin could up-regulate expression of Caveolin-1 protein, which is closely related to cholesterol transport, and reduce intracellular cholesterol levels. Protodioscin has potent HDL and LDL (especially LDL) lowering effects.

Numerous studies have shown that HDL-C concentration is inversely correlated with CVD risk; hence, raising plasma HDL-C levels may protect against CVD. In rats fed a high-cholesterol diet (HCD), supplementation with 0.5/100 g diosgenin for 4 weeks led to a slight increase in serum HDL-C and fecal bile acid levels, and a decrease in lipid droplet size. Sterol regulatory element-binding proteins (SREBPs) regulate the balance of LDL, HDL, and triglyceride levels in vivo. In human THP-1 macrophages, methyl protodioscin (MPD) inhibits SREBP1c and SREBP2 transcription and decreases levels of microRNA 33a/b, which is encoded in SREBP gene introns, leading to a corresponding increase in ATP binding cassette A1 (ABCA1) levels. Since ABCA1 is a key protein in HDL biogenesis, low miR-33a/b levels result in high HDL-C. Further, MPD also decreases expression of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (HMGCR), fatty acid synthase (FAS), and acyl-CoA carboxylase (ACC) genes, which are involved in cholesterol and fatty acid synthesis. Therefore, MPD may increase HDL-C levels, and decrease LDL-C and triglyceride levels.

Scavenger receptor class B type I (SRB1) is a receptor physiologically related to HDL, which participates in reverse transport of cholesterol (RCT) and helps to transport excess cholesterol to the liver in the form of cholesterol ester (CE), and then excrete it into bile and feces. Carboxylesterase 1 (CES-1) exhibits cholesteryl ester hydrolase activity, and contributes to hydrolyzation of HDL-CE to free cholesterol (FC), which is available for bile acid synthesis. Cholesterol 7a-hydroxylase (CYP7A1) is the initial and rate-limiting enzyme in the classical BA synthetic pathway, which regulates the total rate of BA generation. Farnesol X receptor (FXR) is a nuclear receptor with fundamental roles in maintaining BA homeostasis and in maintaining the balance between cholesterol and BA. BAs, specifically hydrophobic BAs, act as ligands for FXR and utilize it in their negative feedback loop. In an in vivo experiment, Yu et al demonstrated that diosgenin (150 or 300 mg/kg/d) can
reduce body weight and blood lipid levels of rats fed a HFD, and significantly improve liver steatosis and intestinal structure. Further, diosgenin can increase the expression of SRB1, CES-1, and CYP7A1 in rat liver and inhibit FXR-mediated signal transduction, as well as increasing SRB1 and CES-1 expression in rat intestine, inhibiting cholesterol absorption, and promoting RCT. Hence, diosgenin promotes RCT and cholesterol clearance through the SRB1/ACES-1/CYP7A1/FXR pathway, which suggests potential new approaches to alleviate hypercholesterolemia. Together, the results above indicate that diosgenin can increase HDL-C and decrease LDL-C and very low-density lipoprotein (VLDL) cholesterol (VLDL-C) levels by regulating cholesterol transport, and thus participate in regulating blood lipid levels.

**Inhibiting Endogenous Lipid Biosynthesis**

HMGCR is an endoplasmic reticulum bound peroxisome enzyme that catalyzes the reduction of HMG-CoA to COA and mevalonate, which is a rate-limiting reaction in the de novo cholesterol biosynthesis pathway; it is highly expressed in the liver and plays a central role in the regulation of cholesterol metabolism.\(^{50}\) It is established that HMGCR inhibitors can effectively reduce plasma cholesterol levels in most animals, including humans and these inhibitors are widely used as statins to reduce cholesterol levels by inhibiting cholesterol synthesis.\(^{51}\) Hao et al showed that oral administration of diosgenin (40 mg/kg orally for 45 days) could significantly reduce mRNA levels encoding HMGCR in the liver of diabetic rats, suggesting that diosgenin can significantly reduce cholesterol synthesis.\(^{52}\) Diosgenin may inhibit cholesterol biosynthesis by blocking the substrate from entering the active site of the HMGCR enzyme. Uemura et al reported that diosgenin (5 and 10 mmol/l) decreased triglyceride content and mRNA expression levels of genes involved in lipid synthesis (FAS, stearoyl-CoA desaturase 1 (SCD-1), and ACC) by inhibiting SREBP-1c mRNA expression, resulting in inhibited lipid accumulation in hepatocellular carcinoma (HepG2) cells.\(^{53}\) A study to investigate the lipid-lowering effects of different granule treatments (50 g/kg 50 mesh-size flour or 50 g/kg nanoscale flour) showed that both *Dioscorea pseudojaponica* particle types could activate adenosine 5’-monophosphate-activated protein kinase (AMPK) and inactivate ACC, as demonstrated by increased levels of phosphorylated enzyme.\(^{54}\) AMPK activation increases the rate of the catalytic (ATP production) pathway and reduces the rate of the anabolic (ATP utilization) pathway.\(^{55}\) Cheng hypothesized that diosgenin can stimulate AMPK activation, promote free fatty acid (FFA) decomposition and, under the synergistic effect of liver X receptor alpha (LXα), inhibit SREBP1C and reduce triglyceride synthesis.\(^{56}\) Poudel et al demonstrated that diosgenin targets the AMPK/MAPK pathway, suppresses mitotic clonal expansion during the early phase of adipogenesis, and decreases the expression of adipogenic transcription factors in 3T3-L1 cells during adipogenesis. At a dose of 4 µM, diosgenin inhibited lipid accumulation in 3T3-L1 cells, but did not affect cell viability. Further, diosgenin can also regulate weight and fat accumulation induced by HFD in obese mice.\(^{57}\) In summary, diosgenin inhibits one or several links in the cholesterol and triglyceride biosynthetic pathways, thereby reducing cholesterol and triglyceride levels.

**Promoting Conversion of Cholesterol into Bile Acid and Excretion**

The classical route for the human body to remove cholesterol lipid is via promotion of cholesterol excretion into biliary cholesterol, the conversion of cholesterol into bile acid, and its subsequent fecal excretion.\(^{58,59}\) The ATP-binding cassette (ABC) transporters, G5 (ABCG5) and G8 (ABCG8), are hemi-transporters, which play an important role in preventing the accumulation of dietary sterols (including cholesterol and phytosterols) in the body.\(^{60}\) Li et al reported that, after treatment with 0.15 or 0.3 g/kg diosgenin, ABCG5/G8 expression was increased in the liver and intestine of HFD rats, suggesting that it can promote bile cholesterol secretion.\(^{21}\) Temel et al showed that fecal excretion of neutral sterols (cholesterol and its bacterial metabolites) in wild-type mice fed with 0.1% diosgenin increased from 4.2 to 52 µmol/day/100 g body weight. Compared with wild-type mice receiving a control diet, the fecal neutral sterol excretion of NPC1L1 knockout mice was also significantly increased, from 63 to 140 µmol/day/100 g body weight. This study demonstrated that diosgenin promotes fecal cholesterol excretion independently of NPC1L1-mediated cholesterol absorption, and that diosgenin may facilitate fecal cholesterol loss to a greater extent in NPC1L1 knockout mice than in wild-type mice.

ABCA1 mediates the transfer of cellular phospholipids (PL) and FC to apolipoprotein A-I (ApoA-I) and related proteins in extracellular medium, acting as a lipid transporter.\(^{62}\) Diosgenin can promote ABCA1 expression.
in macrophages by inhibiting miR-19b levels, and accelerate macrophage cholesterol efflux through the ABCA1 pathway and RCT process.\textsuperscript{63} In HepG2 cells, 25 \(\mu\)m pseudoprotodioscin (PPD), a steroidal saponin similar to diosgenin, significantly increased levels of ABCA1 protein and mRNA, and promoted ApoA-1 mediated cholesterol excretion. The underlying mechanism involves PPD inhibition of SREBP1c and SREBP2 transcription by reducing microRNA33a/b levels, leading to increased ABCA1.\textsuperscript{64} In summary, diosgenin can promote the conversion of cholesterol to bile acid and increase its excretion in various ways; however, details of the complex molecular mechanisms involved remain to be clarified.

### Oxidative Stress and Anti-Oxidant Properties

Oxidation-reduction equilibrium is essential to maintain the normal operation of vital cell functions. Oxidative stress is common in some diseases, including cancer, CVD, atherosclerosis, and diabetes.\textsuperscript{65} Endogenous markers of oxidative stress include superoxide dismutase (SOD), glutathione peroxidase (GPx), and reduced glutathione (GSH). During oxidative stress, phospholipids in cell membranes are oxidized by thiobarbituric acid reactive substances (TBARS), which hinder their biological functions. Diosgenin has potent in vitro anti-oxidative and in vivo anti-inflammatory activities,\textsuperscript{66} and participates in glucose metabolism, reduces oxidative stress, increases cell viability, and decreases reactive oxygen species levels.\textsuperscript{67} Sangeetha et al.\textsuperscript{68} assessed the antioxidant status of experimental rat liver and heart tissue samples treated with and without diosgenin. The rats were fed with an HFD for 8 weeks and then received streptozotocin (STZ) injection to induce a type 2 diabetes model. GSH levels were higher in animals treated with diosgenin (40 mg/kg, 80 mg/kg), although they did not reach the range of those in normal rats. Diosgenin can also maintain SOD and GPX activities and control TBARS production. Rats with chronic renal failure (CRF) were administered diosgenin orally (40 mg/kg/day), and subsequent results demonstrated that diosgenin increased GSH levels and restored endothelial nitric oxide synthase (eNOS) mRNA expression. Further, diosgenin inhibits dyslipidemia and angiotensin converting enzyme (ACE) activity caused by CRF. Overall, data published to date show that diosgenin has potential to protect blood vessels from oxidative stress and dyslipidemia.\textsuperscript{69} Xu et al.\textsuperscript{70} found that dioscin significantly attenuated the increase in malondialdehyde levels caused by ethanol and significantly elevated SOD, GSH, GSH-Px, and GSR levels. These data indicate that dioscin has an excellent protective effect against ethanol-induced liver injury by reducing oxidative stress, inflammatory cytokine production, apoptosis, and liver steatosis. Further, diosgenin acts as an antioxidant in cell membranes, which may provide protection against oxidative damage of polyunsaturated fatty acids.\textsuperscript{71} Fenugreek, which contains diosgenin, can improve glucose metabolism disorder caused by HFD by promoting adipocyte differentiation, inhibiting inflammation of white adipose tissue, and miniaturizing adipocytes.\textsuperscript{72} Numerous studies have demonstrated that diosgenin can regulate blood lipids by removing excessive free radicals and reducing physiological lipid deposition.

### Regulating Lipase Activity

Hepatic lipoprotein lipase (LPL) and hepatic lipase (HL) are important in the process of lipoprotein hydrolysis. Once lipoproteins are transported to the circulation, specific lipases can help to release their lipid components. The secretory dimer lipases, LPL and HL, hydrolyze triglycerides in lipoproteins and provide FFA for tissues. LPL is secreted from the parenchyma of adipose and muscle to the capillary lumen and acts on VLDL and chylous particles. HL is secreted by hepatocytes and acts on residual lipoprotein and HDL rich in cholesterol.\textsuperscript{73} Diosgenin increases LPL and HL activity in a dose-dependent manner. Compared with an HFD rat model group, rats treated with diosgenin (132.8 mg/kg) had significantly increased activities of LPL and HL.\textsuperscript{74}

Pancreatic lipase (PL) is a dietary lipid digestive enzyme, inhibition of which reduces triglyceride digestion and lipid absorption.\textsuperscript{75} Kwon et al.\textsuperscript{76} demonstrated that dioscin and diosgenin have strong inhibitory effects on PL activity. After treatment with dioscin (100 mg/kg) or diosgenin (100 mg/kg), the elevation of plasma triacylglycerol concentration was significantly reduced in mice orally injected with corn oil. Further, in an 8-week experiment, rats fed with a HFD containing 2% or 5% \textit{Dioscorea nipponica} powder exhibited significantly suppressed weight gain and prevented dietary fat absorption relative to controls fed the HFD alone. The cholesterol-lowering effect of saponins and sapogenins has been widely described in literature regarding the treatment of hyperlipidemia. Navarro Del Hierro et al.\textsuperscript{77} found that saponin-rich extracts and their hydrolysates from fenugreek and...
quinoa can inhibit PL activity. Although the exact role of sapogenins contained in the hydrolyzed extracts in lipase inhibition remains unclear, the study provided a potential baseline for the development of multi-bioactive products that act against pancreatic lipase and cholesterol absorption simultaneously. In summary, diosgenin reduced dietary fat decomposition and absorption in the digestive organs by reducing the hydrolytic activity of these key enzymes, thus alleviating the symptoms of metabolic diseases, such as hyperlipidemia. In future, the regulation of lipase activity by diosgenin warrants further research.

Regulating Transcription Factors Related to Lipid Metabolism

The metabolic enzymes and receptors involved in lipid metabolism are regulated by various transcription factors. Molecules established as involved in lipid metabolism include SREBP-1, LXRs, and peroxisome proliferator activated receptors (PPAR). SREBP-1c preferentially enhances the transcription of genes required for fatty acid synthesis, which is a key regulator of lipid synthesis and accumulation. Diosgenin can inhibit the increased expression of the sterol regulatory element-binding protein, SREBP-1, and that of its target genes, including FAS, SCD-1, and ACC. Mechanistic studies demonstrated that dioscin can regulate the expression levels of downstream proteins, including SREBP-1c, carnitine palmitoyl transferase, FAS, SCD, forkhead box O1, and adipose triglyceride lipase, by regulating the Silent information regulator of transcription 1 (SIRT1)/AMPK signaling pathway, thus significantly reducing lipid metabolism. One study reported significant down-regulation of ACC and FAS, alongside up-regulation of PPARγ and LDL receptor (LDLR), genes at the mRNA level in SW480 cell lines treated with 6.21 µg/mL diosgenin. These findings indicate that SREBP is a key hub in diosgenin regulation of abnormal lipid metabolism.

LXRs, particularly liver LXRA, have important roles in the transcriptional regulation of lipid metabolism. As a cholesterol sensor, the nuclear receptor, LXR, is a crucial factor in regulating cholesterol homeostasis. LXRA activation can promote the RCT process, cholesterol catabolism, and cholesterol excretion. By contrast, LXRs, particularly liver LXRA, have important roles in regulating cholesterol homeostasis. Activated LXRs can promote cholesterol metabolism; however, they inevitably produce classical lipogenic side effects. SREBP1 is a significant target of LXRA in upregulating lipogenesis, LXRA enhances fatty acid synthesis by activating SREBP1c transcription, which in turn transactivates lipogenic genes. LXRA directly regulates the expression of specific lipogenic genes, including acetyl-CoA carboxylase a (ACACA) in chick embryos and fatty acid synthase (FASN) in human cells. Diosgenin (10, 25, and 50 µM) significantly inhibited the accumulation of TG and the increase of SREBP-1c mRNA in HepG2 cells induced by high glucose levels. In addition, compared with the model group, diosgenin (0.5% or 1% w/w) treated rats fed with a HFD also exhibited significantly suppressed LXRA levels. These data demonstrate that diosgenin may influence fatty acid metabolism by regulating the LXRA/SREBP-1c signaling pathway. To date, there has been insufficient study of whether diosgenin can regulate cholesterol metabolism-related pathways through LXRs to maintain cholesterol homeostasis. It will be of great significance to further ascertain the specific mechanism underlying diosgenin-mediated regulation of LXRs.

PPARs are members of the nuclear receptor superfamily, and their physiological functions are related to metabolism, energy homeostasis, and cell development and differentiation. Three PPARs have been identified: PPARα, PPARγ, and PPARβ/δ. Many PPAR agonists have been synthesized to treat metabolic diseases, particularly dyslipidemia and type 2 diabetes mellitus (T2DM), due to their crucial metabolic regulatory roles and excellent druggability. Hepatic PPARα stimulates fatty acid catabolism by modulating the expression of LPL, apolipoprotein genes, fatty acid transport and oxidation genes, and genes involved in HDL metabolism and ketone synthesis. Therefore, PPARα activators have vital roles dyslipidemia treatment. Sangeetha et al detected a slight increase in PPARα expression in 3T3-L1 cells treated with diosgenin at 0.5, 1, and 10 µM, but the increase was not as significant as that of PPARγ. PPARγ is mainly expressed in adipose tissue, hematopoietic cells, and the large intestine, and has key roles in lipid and glucose metabolism. PPARγ agonists are widely used for T2DM treatment and their clinical efficacy as oral antidiabetic agents is well...
established, however, there is controversy about the effect of diosgenin on PPARγ, one study showed that diosgenin can down-regulate PPARγ expression and activity, and inhibit adipocyte differentiation. Another study showed that diosgenin is a selective agonist of PPARγ and up-regulates its expression. This may be why adipogenesis was observed in 3T3-L1 cells, resulting in reduced circulating free lipids in diabetic animals, and diosgenin may be considered as a hypolipidemic drug. At present, the mechanism underlying of the effects of diosgenin on PPARs are unclear. In silico docking studies showed that PPARα and PPARγ both interact with diosgenin, while the efficiency of diosgenin binding to PPARγ is higher than that of PPARα. This raises a question of whether diosgenin may be a dual agonist of both PPARα and PPARγ. A recent study showed that integrative application of PPARα and PPARγ agonists may decrease hepatic lipid accumulation, oxidative stress, and production of inflammatory cytokines, which may be due to the synergistic effect of PPARα and PPARγ in regulating the expression of the downstream target genes, SREBP-1c, FAS, DGAT, LPL, and NF-jB. As synthetic ligands have many side effects, using natural agonists, such as diosgenin, may be a safe alternative method for targeted regulation of lipid metabolism. Diosgenin can also be considered a dual agonist, which could provide a better balance between efficacy and side effects, compared with single agonists or dual agonists with varying potency.

In summary, diosgenin participates in regulating lipid metabolism through multiple targets and pathways. The underlying mechanisms are highly complex and more animal studies and clinical trials are needed to unravel the details in the future.

Advantages and Limitations of Diosgenin

Plant extracts and their derivatives are widely used to treat various diseases because of their high bioavailability, low side effects, and low cost. In recent years, diosgenin and its derivatives have been the focus of considerable research efforts worldwide. Numerous studies have elucidated the pharmacological effects of diosgenin and its derivatives on various diseases, such as cancer, diabetes, and osteoporosis. Diosgenin can be obtained from various medicinal plants, particularly fenugreek seeds, which represent a comprehensive and low-cost source. In general, diosgenin and other plant-derived compounds have lower toxicity than chemical drugs. Notably, diosgenin has good cytotoxic activity toward HepG2 cells, but relatively low toxicity to L02 cells, indicating a degree of selectivity between normal and tumor cells. We infer that steroidal saponins, including diosgenin, do not show any significant toxicity at conventional dosages. Due to the poor water solubility and strong hydrophobicity of diosgenin, its oral bioavailability is not ideal, and numerous diosgenin formulation strategies have been applied to overcome these issues, including liquid crystalline (LCs) and b-cyclodextrin (b-CD) complexes, nanocrystals, and soluplus-mediated diosgenin Amorphous Solid Dispersion (ASD) technology. In recent decades, ASDs have been the subject of increased research interest, as they can increase the oral bioavailability of poorly soluble drugs. The aqueous solubility of optimized ASDs was significantly improved due to the amorphanization of diosgenin and the molecular interactions between diosgenin and soluplus. Furthermore, pharmaco-kinetic studies in rats revealed that the bioavailability of diosgenin from ASDs was improved approximately five-fold. Hence, diosgenin ASDs, with their high solubility, high bioavailability, and high stability, represent a promising route toward pharmaceutical applications. Simultaneously, although numerous preclinical studies have demonstrated that diosgenin has reliable lipid metabolism regulation function, clinical research data remain limited. Therefore, it will be necessary to verify the therapeutic effects of diosgenin on human hyperlipidemia via additional clinical trials in the future.

Conclusion and Future Prospects

Phytochemicals found in medicinal or edible plants have remarkable biological activity, high safety, low or no toxicity, and represent alternative resources for developing new drugs. Diosgenin is a natural steroidal saponin, with potential for broad application. Numerous studies have confirmed the great potential for use of diosgenin in the treatment and prevention of hyperlipidemia. In this paper, we reviewed the pharmacological mechanism underlying the effects of diosgenin in the treatment of hyperlipidemia, including its roles in inhibition of intestinal lipid absorption, regulation of cholesterol transport, promotion of cholesterol conversion into bile acid and excretion, inhibition of endogenous lipid biosynthesis, effects on antioxidation and lipoprotein lipase activity, and regulation of transcription factors related to lipid metabolism. Combined with research progress regarding
the pathological mechanism underlying dyslipidemia, related pathways were discussed. Drugs to treat dyslipidemia mainly reduce blood lipids by regulating the kinetics of different parts of the metabolic cycle. Researchers worldwide are using network pharmacology, chromatography, mass spectrometry, and GCMS to study the pathogenesis and treatment of hyperlipidemia and the resulting findings will provide a scientific basis for understanding the “multi component-multi target-multi pathway” mechanisms underlying the effects of diosgenin on hyperlipidemia.

In addition, several new diosgenin delivery systems have been developed by combining diosgenin with β-CD, LC, nanocrystalline, and ADS technologies, to improve the water solubility and bioavailability of the compound, which has been beneficial to the clinical application and biological activity of diosgenin. Drugs containing diosgenin are already marketed in China; however, there have been few reports on clinical trials of diosgenin for treating dyslipidemia, making it difficult to assess the potential clinical benefits of diosgenin for treating human hyperlipidemia. Thus, more clinical trials are needed to ensure the effectiveness and safety of diosgenin when used to regulate human lipid metabolism. Diosgenin could be used as a small molecule probe to search for natural-binding partners in vivo that play important roles in reducing blood lipids. In the future, with further study on the mechanisms underlying diosgenin activity, diosgenin can be expected to play a safer and more effective pharmacological role and be appropriately applied in the treatment of disease in the clinic.

Abbreviations
CHD, coronary heart disease; VLDL-C, very low-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; CVD, cardiovascular disease; CV, cardiovascular; VLDL, very low-density lipoprotein; LDL, low-density lipoprotein; LDLR, low-density lipoprotein receptor; IDL, medium-density lipoprotein; HDL, high-density lipoprotein; SD, Sprague–Dawley; HFD, high-fat diet; HCD, high-cholesterol diet; NPC1L1, Niemann-Pick C1-Like 1; SREBPs, Sterol regulatory element-binding proteins; SREBP-1, sterol regulatory element-binding protein; SREBP-2, sterol regulatory element-binding protein-2; MPD, methyl protodioscin; ABCA1, ATP binding cassette A1; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; FAS, fatty acid synthase; ACC, acetyl-CoA carboxylase; SRB1, scavenger receptor class B type I; RCT, reverse transport of cholesterol; CE, cholesterol ester; CES-1, carboxylesterase 1; FC, free cholesterol; CYP7A1, cholesterol 7α-hydroxylase; BA, bile acid; FXR, farnesol X receptor; FAS, fatty acid synthase; SCD-1, stearoyl-CoA desaturase 1; ACC, acetyl-CoA carboxylase; HepG2, hepatocellular carcinoma; AMPK, adenosine 5’-monophosphate-activated protein kinase; FFA, free fatty acids; LXR, liver X receptor; LXRα, liver X receptor alpha; ABCG5, ATP-binding cassette transporters G5; ABCG5, ATP-binding cassette transporters G8; PL, phospholipids; ApoA-I, apolipoprotein A-I; PPD, pseudoprotodioscin; SOD, superoxide dismutase; GPx, glutathione peroxidase; GSH, glutathione; TBARS, thiobarbituric acid reactive substances; ROS, reactive oxygen species; STZ, streptozotocin–Induced; CRF, chronic renal failure; eNOS, endothelial nitric oxide synthase; ACE, angiotensin converting enzyme; MDA, malondialdehyde; LPL, lipoprotein lipase; HL, hepatic lipase; PL, pancreatic lipase; PPAR, peroxisome proliferator activated receptors; NADPH, nicotinamide adenine dinucleotide phosphate; SIRT1, silent information regulator of transcription 1; ACACA, acetyl-CoA carboxylase α; FASN, fatty acid synthase; T2DM, type 2 diabetes mellitus; L02, normal human liver cells; LCs, liquid crystalline; b-CD, b-cyclodextrin; ASD, amorphous solid dispersion; SPF, specific-pathogen-free; Mest, mesoderm specific transcript; HepG2, hepatocellular carcinoma; AMPK, adenosine monophosphate-activated protein kinase; FFA, free fatty acids; LXR, liver X receptor; LXRα, liver X receptor alpha; ABCG5, ATP-binding cassette transporters G5; ABCG5, ATP-binding cassette transporters G8; PL, phospholipids; ApoA-I, apolipoprotein A-I; PPD, pseudoprotodioscin; SOD, superoxide dismutase; GPx, glutathione peroxidase; GSH, glutathione; TBARS, thiobarbituric acid reactive substances; ROS, reactive oxygen species; STZ, streptozotocin–Induced; CRF, chronic renal failure; eNOS, endothelial nitric oxide synthase; ACE, angiotensin converting enzyme; MDA, malondialdehyde; LPL, lipoprotein lipase; HL, hepatic lipase; PL, pancreatic lipase; PPAR, peroxisome proliferator activated receptors; NADPH, nicotinamide adenine dinucleotide phosphate; SIRT1, silent information regulator of transcription 1; ACACA, acetyl-CoA carboxylase α; FASN, fatty acid synthase; T2DM, type 2 diabetes mellitus; L02, normal human liver cells; LCs, liquid crystalline; b-CD, b-cyclodextrin; ASD, amorphous solid dispersion; SPF, specific-pathogen-free; Mest, mesoderm specific transcript; MCP-1, monocyte chemoattractant protein; CM, chylomicron; PCSK9, proprotein convertase subtilisin/kexin type 9.

Acknowledgments
We want to thank Liping Zhang for her timely help in revising the grammar and logic of the manuscript. This paper was supported by the National Natural Science Foundation of China (No. 81573945), the Science and Technology Development Project of Shandong Province (No. 2013GSF11902), the National Prestigious Chinese Medicine Doctor Studio of Xinlu Wang Project ([2016]47), and the Science and Technology Development Project of Traditional Chinese Medicine in Shandong Province (Nos. 2013-081 and 2019-0093).

Disclosure
The authors report no conflicts of interest in this work.


56. Cheng SL. The Action and Mechanism of Diosgenin Suppress the Nonalcoholic Fatty Liver Disease. Second Military Medical University; 2014.


60. Patel SB, Graf GA, Temel RE. ABCG5 and ABCG8: more than a defense against xenosterols. J Lipid Res. 2018;59(7):1103–1113. doi:10.1194/jlr.R084244


